Associated Papers
Integration of metabolomic and genetic data reveals novel variants underpinning the human metabolome: the Coronary Artery Risk Development in Young Adults (CARDIA) study.
Krishnan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2026
Characterisation of pharmacogenomic variation in the Shetland and Orkney Isles in Scotland.
Twesigomwe D et al.
Scientific Reports, 2025
Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.
Ortega-Ayala A et al.
Pharmaceuticals (basel, Switzerland), 2025
Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.
Ortega-Ayala A et al.
Biomedicines, 2025
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
Thuy VT et al.
Leukemia Research, 2025
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
Genetic Variants of SLC22A1 rs628031 and rs622342 and Glycemic Control in T2DM Patients from Northern Mexico.
Moreno-González JG et al.
Genes, 2025
Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans.
Blöcher JA et al.
Clinical Pharmacology and Therapeutics, 2025
Insights Into Genetic Variations of the OCT1 Gene in Metformin Poor Responders Among Bangladeshi Type 2 Diabetic Patients.
Begum R et al.
Advances in Pharmacological and Pharmaceutical Sciences, 2025
Metformin efficacy and tolerance according to genetic polymorphisms of organic cation transporter 1 in Tunisian patients with type 2 diabetes.
Chaker F et al.
Frontiers in Endocrinology, 2025
Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.
Khwarg J et al.
Clinical and Translational Science, 2024
Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes.
AlKreathy HM et al.
Medicine, 2024
The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.
Yee SW et al.
Molecular Cell, 2024
Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population.
Sivadas A et al.
Bmj Open Diabetes Research & Care, 2024
Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes.
Ahmed A et al.
Research in Pharmaceutical Sciences, 2023
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors.
Xiu F et al.
International Journal of Molecular Sciences, 2023
Association of Met420del Variant of Metformin Transporter Gene SLC22A1 with Metformin Treatment Response in Ethiopian Patients with Type 2 Diabetes.
Degaga A et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2023
Rescue of Misfolded Organic Cation Transporter 3 Variants.
Angenoorth TJF et al.
Cells, 2022
Atypical Substrates of the Organic Cation Transporter 1.
Redeker KM et al.
Biomolecules, 2022
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
Nies AT et al.
Pharmacology & Therapeutics, 2022
Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.
Nasykhova YA et al.
Genes, 2022
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.
Zhou Y et al.
Human Genetics, 2022
Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes.
Kawoosa F et al.
Bmc Endocrine Disorders, 2022
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients.
Kuhlmann I et al.
Basic & Clinical Pharmacology & Toxicology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Emerging Roles of the Human Solute Carrier 22 Family.
Yee SW et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Genetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and "Missing" Heritability.
Martín-Campos JM
Biomedicines, 2021
Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C et al.
British Journal of Pharmacology, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches.
Sayed S et al.
Advances in Experimental Medicine and Biology, 2021
Expansion of Knowledge on OCT1 Variant Activity In Vitro and In Vivo Using Oct1/2-/- Mice.
Morse BL et al.
Frontiers in Pharmacology, 2021
Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1.
Römer S et al.
Frontiers in Pharmacology, 2021
Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport.
Jensen O et al.
Frontiers in Pharmacology, 2021
Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.
Matthaei J et al.
Frontiers in Pharmacology, 2021
The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review.
Baye AM et al.
Frontiers in Genetics, 2021
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.
Venkatachalapathy P et al.
Pharmacogenomics and Personalized Medicine, 2021
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease.
Nielsen JB et al.
Nature Communications, 2020
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
Cabral LKD et al.
Cancers, 2020